ACTRIMS 2021 | Is long-term teriflunomide treatment safe in MS?
Mark Freedman, MSc, MD, CSPQ, FAAN, FRCPC, University of Ottawa & Ottawa Hospital Research Institute, Ottawa, Canada, shares the findings of a pooled analysis of four Phase III randomized clinical trials, assessing the impact of long-term teriflunomide treatment on lymphocyte counts and infection rates in patients with multiple sclerosis (MS). Over 1800 patients were analyzed from the TEMSO, TOWER, TENERE, and TOPIC trials. The results showed that long-term risk of lymphopenia and infections were low in patients receiving continued teriflunomide treatment. No late-stage problems were seen that were not identified early on. This interview took place during the ACTRIMS Forum 2021.
Disclosures
Research or educational grants: Sanofi-Genzyme Canada, Hoffman-La Roche, EMD Inc. (Canada)
Honoraria or consultation fees: Actelion (Janssen/J&J), Alexion, BiogenIdec, Celgene (BMS), EMD Inc., Sanofi-Genzyme, Hoffman La-Roche, Merck Serono, Novartis, Teva Canada Innovation
Member of a company advisory board, board of directors or other similar group: Actelion (Janssen/J&J), Alexion, Atara Biotherapeutics, BayerHealthcare, BiogenIdec, Celgene (BMS), Clene Nanomedicine, GRI Bio, Hoffman La-Roche, Magenta Therapeutics, Merck Serono, Novartis, Sanofi-Genzyme, Teva Canada Innovation
Company sponsored speaker’s bureau: Sanofi-Genzyme, EMD Serono
